Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Genitourinary 2Breast 2Tumor-Agnostic 1Plasma cell 1Myeloid 1CNS 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 510Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ranitidine × Lymphoid × Clear all
NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02999633 2022-03-21

ISLAY

Sanofi

Phase 2 Terminated
14 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡